1
Clinical Trials associated with Sargramostim therapy(Innoventus Project AB)A Phase I, Open-Label, Single Center, Safety/Tolerability and Pharmacokinetic Study of Leukine® Administrated in the Gingiva as Three Single Doses on Separate Days
This exploratory study is the first study in a clinical program where the overall objective is to develop a novel pharmaceutical therapy comprising local administration of GM-CSF for the treatment of periodontitis. The project hypothesis is based on GM-CSF's antibacterial and putative bone regeneration properties. Periodontitis is the major cause of tooth loss in people over 35 years of age. An effective pharmacological treatment is today lacking and the actual therapy would represent a new treatment option for the large patient group suffering from the disease.
100 Clinical Results associated with Sargramostim therapy(Innoventus Project AB)
100 Translational Medicine associated with Sargramostim therapy(Innoventus Project AB)
100 Patents (Medical) associated with Sargramostim therapy(Innoventus Project AB)
100 Deals associated with Sargramostim therapy(Innoventus Project AB)